Antimicrobial resistance Archives

Leuven biotech of the week wikimedia Edited

Startup Scout 5 Oct 2018

This Biotech Sticks Bacterial Proteins Together to Fight Antibiotic Resistance

This week’s biotech has its base in Leuven, Belgium. The newly-founded Aelin Therapeutics hopes to combat antibiotic resistance by doing the pharmacological equivalent of boiling an egg. Mission: To develop a new type of drugs to kill bacteria that are resistant to antibiotics. In the future, the drugs could also be used to kill pathogenic […]

October 5, 2018 - 3 minutesmins - By Jonathan Smith

News and Trends 3 Aug 2018

Precision Antibiotic Improves Outcome of Gut Infections in Phase II

Summit Therapeutics obtained Phase II results showing its antibiotic for C. difficile infections was more effective in reducing the recurrence of the disease than the standard of care. Clostridium difficile is a bacterium that can infect the gut after a patient receives broad spectrum antibiotics. C. difficile infections typically cause diarrhoea and abdominal pain, but […]

August 3, 2018 - 2 minutesmins - By Alexander Burik

In Depth 25 Jul 2018

Could These Groundbreaking Therapies Make Conventional Antibiotics a Thing of the Past?

With the rise of antimicrobial resistance across the globe, and with a dire lack of new antibiotics in the pipeline, more attention is going towards developing innovative treatments and technologies that kill superbugs in completely new ways. Here, we take a closer look at some of the most promising of these technologies emerging from the […]

July 25, 2018 - 5 minutesmins - By Farhan Mitha

News and Trends 13 Jul 2018

French Biotech Raises €12.5M for Antibiotic Booster Drugs

French-biotech Antabio closed €12.5M at series A to fund its pipeline of antibiotic booster drugs that should help in the global fight against antimicrobial resistance. After raising €7.3M last year, Antabio extended its Series A financing round with €5.2M of additional funding raised from private investors. The French biotech will use the funding to continue […]

July 13, 2018 - 2 minutesmins - By Alexander Burik

antimicrobial resistance molecular diagnostics 1

Interview 3 Jul 2018

Fighting Antimicrobial Resistance with Fast Molecular Diagnostics

Antimicrobial resistance is predicted to kill more people than cancer by 2050. Is it possible to prevent it? At our Refresh Meetup in Berlin, I talked with Achim Plum, CBO of the diagnostics company Curetis, about what are our best bets to turn the tables in the fight against the threat of antimicrobial resistance. The […]

July 3, 2018 - 8 minutesmins - By Clara Rodríguez Fernández

Nabriva Therapeutics Pneumonia Antibiotic

News and Trends 23 May 2018

Another Pneumonia Antibiotic is Close to Treating Patients

Nabriva Therapeutics has obtained positive Phase III results for its antibiotic lefamulin and plans to seek FDA approval for the drug by the end of this year. Nabriva Therapeutics has obtained a second round of positive Phase III results for lefamulin, its antibiotic targeting community-acquired pneumonia. The drug was shown to be as effective as […]

May 23, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 15 May 2018

Swiss Company Raises Ambitious IPO to Fight Antibiotic Resistance

Polyphor has closed an IPO of CHF 165M (€138M) to continue developing a new class of antibiotics against pneumonia, as well as treatments for cystic fibrosis and breast cancer. Polyphor, based in Switzerland, has raised a substantial IPO of CHF 165M (€138M) on the SIX Swiss Exchange, surpassing its initial goal of CHF150M (€127M). The funds will […]

May 15, 2018 - 2 minutesmins - By Alexander Burik

Startup Scout 27 Apr 2018

This Portuguese Biotech is Developing a Faster Antimicrobial Susceptibility Test

Today, we’re in Matosinhos, Portugal, visiting FASTinov, a biotech that is developing an antimicrobial susceptibility test that are faster than standard assays. The technology could help battle antibiotic resistance by identifying appropriate treatments. Mission: Founded in 2013, FASTinov is developing a new type of test for antimicrobial susceptibility that can help combat the global health problem of antibiotic […]

April 27, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 24 Apr 2018

New Class of Antibiotics Combats the Three Deadliest Bacteria in the World

A new class of antibiotics developed by Polyphor has been shown to be effective against the three most dangerous drug-resistant bacteria in the world. Polyphor’s novel class of antibiotics has been shown to effectively combat the three bacteria marked as critical, priority 1 by the World Health Organization. To date, there are very limited to no […]

April 24, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 18 Apr 2018

Finnish Rapid Molecular Diagnostic Test Enters European Market

Mobidiag, a Finnish biotech, has launched a diagnostic test that can rapidly detect the most common disease-causing microbes in the gut. The test can help manage infections more effectively at an earlier stage. Mobidiag has launched a molecular diagnostic test on the European market that checks patient samples for numerous bacterial targets, including the most […]

April 18, 2018 - 1 minutemin - By Alexander Burik

Startup Scout 30 Mar 2018

This French Biotech Detects Microbes With a “Molecular Hook”

Today we are in the sunny Marseille, on the South coast of France, visiting Click4Tag, a biotech developing a molecular hook to attach to and detect microbial membranes. Its unusual principle has both environmental and medical applications. Mission: Founded in 2014, Click4Tag is developing a unique technology to detect microorganisms. The company introduces a “molecular hook” into […]

March 30, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Allecra Therapeutics Urinary Tract Infections

News and Trends 26 Mar 2018

New Antibiotic for Urinary Tract Infections Gets Positive Phase II Results

Allecra Therapeutics has obtained positive Phase II study results for its new urinary tract infection antibiotic, supporting the launch of a Phase III trial. Allecra Therapeutics, a French-German biotech, has obtained positive Phase II trial results for its lead antibiotic candidate for treating urinary tract infections. The drug, AAU101, was given to patients intravenously with cefepemine, another antibiotic […]

March 26, 2018 - 1 minutemin - By Alexander Burik

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us